In non-small cell lung cancer (NSCLC), IL-6 induces EMT, resulting in cisplatin resistance [152], while melanoma circumvents BRAF inhibition by reactivating downstream pathways (i.e., MAPK, PI3K-AKT) through c-Met activation via CAF-derived HGF (Hepatocyte Growth Factor) [153]. Here, BRAF is linked to non-small cell lung carcinoma.